Stock RAPT RAPT THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-12 EDT 		5-day change 1st Jan Change
3.55 USD -3.79% Intraday chart for RAPT Therapeutics, Inc. -14.87% -85.71%
05-14 Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform MT
05-10 Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy MT

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform
MT
Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy
MT
Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4
MT
JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating
MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61
MT
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating
MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10
MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy
MT
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15
MT
Stifel Cuts RAPT Therapeutics' Price Target to $33 From $40, Keeps Buy Rating
MT
Piper Sandler Cuts RAPT Therapeutics' Price Target to $18 From $31, Keeps Overweight Rating
MT
Cantor Fitzgerald Downgrades RAPT Therapeutics to Neutral From Overweight
MT
Evercore ISI Starts Coverage on RAPT Therapeutics With Outperform Rating
MT
Wolfe Research Starts RAPT Therapeutics With Outperform Rating, $39 Price Target
MT
RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
CI
Berenberg Initiates RAPT Therapeutics With Buy Rating, Price Target is $34
MT
JPMorgan Adjusts Price Target on RAPT Therapeutics to $32 From $39, Maintains Overweight Rating
MT
Piper Sandler Adjusts Price Target on RAPT Therapeutics to $31 From $28, Maintains Overweight Rating
MT
Stifel Initiates Coverage on RAPT Therapeutics with Buy Rating, $40 Price Target
MT
Barclays Initiates RAPT Therapeutics With Overweight Rating, $35 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RAPT Stock
  4. News RAPT Therapeutics, Inc.
  5. Analyst Reco.